Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country
he US FDA has issued six observations pursuant to the completion of the audit.
He was appointed a Board member and the Chairman in 2012.
Strides is the first Indian company to get approval for the product.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar
Subscribe To Our Newsletter & Stay Updated